Introduction
Pain is an adaptive warning signal under physiological conditions, but it also causes a lot of suffering during various pathological states. Pain is a complex phenomenon with many components. The sensory component provides information about location, intensity, and quality of the painful event (1) . In addition, pain is inherently unpleasant and induces a negative affective state (2, 3) . Converging evidence indicates that the brain regions mediating the sensory and the affective components of pain are, at least partly, distinct (1, (4) (5) (6) .
Prostaglandins are key regulators of nociceptive processing during inflammation, and prostaglandin synthesis inhibitors in the form of nonsteroidal antiinflammatory drugs are widely used for their analgesic properties. Prostaglandins modulate nociceptive signaling at many levels of the neuraxis (7), but it is unclear how they are involved in the affective dimension of pain.
Results and Discussion
To investigate the affective component of pain in mice, we used conditioned place avoidance induced by inflammatory pain. This test, in which mice learn to avoid a chamber where they experienced pain induced by formalin injection to the hind paw, has been used extensively to investigate the affective component of pain in rodents (3, 5, 6, 8) . To explore the role of prostaglandins, we first interfered with the cyclooxygenases COX1 and COX2 (also known as PTGS1 and PTGS2), enzymes responsible for prostaglandin synthesis. Normal (WT) mice, mice lacking COX1, and mice pretreated with a COX1 selective inhibitor (sc560, 5 mg/kg, i.p.; Figure 1B Figure 1 ; supplemental material available online with this article; https://doi.org/10.1172/JCI90678DS1). In contrast, the aversion was completely blocked in genetically modified mice lacking COX2 activity ( Figure 1C ) and when COX2 was inhibited (parecoxib, 10 mg/kg) during the pain sessions ( Figure 1D ). To identify the cell type producing the critical prostaglandins, we next used the Cre/loxP system to delete Cox2 in specific cell types. Mice without COX2 in myeloid cells (Cox2 fl/fl LysM-Cre; Figure 1E ) or in brain endothelial cells (Cox2 fl/fl Slco1c1-Cre mice; Figure 1F ) displayed aversion comparable to that of littermates without Cre (WT mice). In contrast, mice without COX2 in neural cells (Cox-2 fl/fl Nes-Cre mice), including peripheral and central neurons and glia, showed no avoidance behavior ( Figure 1G) . Prostaglandin E 2 is the principal proinflammatory prostanoid and an important regulator of nociceptive and systemic inflammatory responses (7, (9) (10) (11) . We tested mice lacking mPGES-1, the inducible form of prostaglandin E synthase, in our pain model (mPges-1 KO mice). These mice displayed significantly lower aversion scores compared with their WT littermates ( Figure 1H ). Prostaglandin E 2 binds to 4 G protein-coupled receptors called EP 1 to EP 4 (encoded by Ptger1-4). We tested mice lacking EP 1 or EP 3 receptors, since these are strongly expressed in brain structures related to motivation (12, 13) and have been shown to be implicated in nociceptive processing (14) (15) (16) Pain is fundamentally unpleasant and induces a negative affective state. The affective component of pain is mediated by circuits that are distinct from those mediating the sensory-discriminative component. Here, we have investigated the role of prostaglandins in the affective dimension of pain using a rodent pain assay based on conditioned place aversion to formalin injection, an inflammatory noxious stimulus. We found that place aversion induced by inflammatory pain depends on prostaglandin E 2 that is synthesized by cyclooxygenase 2 in neural cells. Further, mice lacking the prostaglandin E 2 receptor EP 3 selectively on serotonergic cells or selectively in the area of the dorsal raphe nucleus failed to form an aversion to formalininduced pain, as did mice lacking the serotonin transporter. Chemogenetic manipulations revealed that EP 3 receptor activation elicited conditioned place aversion to pain via inhibition of serotonergic neurons. In contrast to their role in inflammatory pain aversion, EP 3 receptors on serotonergic cells were dispensable for acute nociceptive behaviors and for aversion induced by thermal pain or a κ opioid receptor agonist. Collectively, our findings show that prostaglandin-mediated modulation of serotonergic transmission controls the affective component of inflammatory pain.
Prostaglandin-mediated inhibition of serotonin signaling controls the affective component of inflammatory pain 1 ly, these findings strongly suggest that ascending serotonergic transmission is critical for pain-induced aversion and that prostaglandin E 2 can modulate such transmission by a direct effect on EP 3 receptors on serotonergic neurons. Since most EP 3 R splice variants are coupled to inhibitory G proteins, we investigated whether EP 3 R activation elicits aversion by inhibition of serotonergic neurons. To test this, we used a designer receptor exclusively activated by designer drug-based (DREADD-based) chemogenetic approach (19) to maintain firing in serotonergic cells during the painful experience and monitored the aversive response of the mice. We injected viral vectors with Cre-dependent expression of Gq-coupled DREADDs (hM3Dq) or mCherry in SERT-Cre mice (AAVhM3Dq Sert-Cre and AAV-mCherry Sert-Cre mice, respectively; Figure 2I ) and activated the cells by administration of clozapine N-oxide (CNO) before the formalin injections. Strikingly, chemogenetic activation of serotonergic cells blocked the aversion ( Figure 2J ). Further, mice without EP 3 Rs on serotonergic cells, which normally display no pain-induced aversion, showed a normal aversion when their serotonergic cells were inhibited during the formalin-pain session ( Figure 2 , K and L). This was achieved by stereotaxic injections of AAVs encoding Gicoupled DREADDs (hM4Di) or mCherry in EP3R-SERTCre mice (AAV-hM4Di EP3R-SERTCre and AAV-mCherry EP3R-SERTCre mice, respectively; Figure 2K ).
Next, we investigated whether the prostaglandin-dependent pathway identified was specific to the affective component of pain or whether it was necessary for all aspects of pain. We monitored acute formalin-induced nociceptive behaviors (lifting, shaking, and licking the injected paw) in mice subjected to pharmacological inhibition of COX2 in mPGES-1 KO mice and in EP3R-SERTCre mice. Pharmacological inhibition of COX2, as well as lack of mPGES-1, markedly reduced the nociceptive behaviors in the second phase of the formalin test (Figure 3 , A and aversion scores compared with WT littermates (Figure 2A ). In contrast, Ptger3 knockout (EP3R KO) mice displayed no pain-induced aversion ( Figure 2B ). EP 3 receptors are expressed in many structures of the brain and the spinal cord. Given the important role of serotonin in the regulation of affective functions, the EP 3 receptor expression in serotonergic neurons of the dorsal raphe nucleus and other serotonergic structures (12) is particularly interesting in the context of aversion. To explore the role of EP 3 receptors on serotonergic neurons, we next used Ptger3 fl/fl Sert-Cre mice (referred to as EP3R-SERTCre mice). In these mice, Ptger3 is deleted by Cre expressed under control of the serotonin transporter (Sert) promoter. As expected, Cre expression was specific to serotonergic neurons, identified by labeling for tryptophan hydroxylase (TpH) (Figure 2, C and D) . Further, EP3R-SERTCre mice displayed a clear reduction of Ptger3-α mRNA in tissue punches from the dorsal raphe region, whereas no reduction was seen in the cortex or the hypothalamus/thalamus (Supplemental Figure 2A ). Subsequently, we tested the EP3R-SERTCre mice in the conditioned pain-avoidance test. We observed a complete abrogation of the aversion in EP3R-SERTCre mice ( Figure 2E ). Further, aversion was completely blocked in mice lacking the serotonin transporter SERT ( Figure 2F ). The serotonergic system can be divided into 2 main parts (17) . One is ascending, involved in affective processing, and is constituted by the dorsal and median raphe nuclei. The other is descending and modulates nociceptive processing in the spinal cord (17, 18) . To determine whether the ascending serotonergic pathways mediated the aversion, we deleted Ptger3 receptors in the region of the dorsal raphe nucleus. This was done by stereotaxic injection of Cre-expressing viral vectors (AAV5) into mice with floxed Ptger3. Mice with injections that affected the dorsal raphe nucleus ( Figure 2G ) without extending to the descending raphe nuclei showed blocked aversion ( Figure 2H ). Collective- B), whereas they were unaffected in EP3R-SERTCre mice (Figure 3, C and D) . This indicates that prostaglandin E 2 modulates many components of pain, but that the effect on serotonergic transmission selectively controls the affective dimension. We also found a normal febrile response in EP3R-SERTCre mice ( Figure 3E ), indicating that responses driven by EP 3 Rs in nonserotonergic cells were intact (20, 21) . Further, aversion induced by the κ opioid receptor agonist U-50488 (2.5 mg/kg, i.p.) was intact in EP3R-SERTCre mice ( Figure 3F as prostaglandins and serotonin modulate nociceptive processing at many levels, this mechanism selectively regulates the affective dimension of inflammatory pain.
Methods
Additional methods are provided in the Supplemental Methods.
Statistics. All the data are expressed as mean ± SEM and were analyzed (in GraphPad Prism) using 2-tailed Student's t tests, except for body temperature measurements, which were analyzed with 2-way ANOVA. P < 0.05 was considered significant. The number of mice are specified in Supplemental Figure 1 or the figure legends.
Study approval. All experiments were approved by the Linköping Animal Care and Use Committee and followed national and international guidelines.
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In summary, we show that persistent inflammatory pain induces aversion through a mechanism involving neural prostaglandin synthesis and EP 3 receptors on serotonergic cells. Where- Nes-Cre mice (G) and EP3R-SERTCre mice (H) and their WT littermates. **P < 0.01; ***P < 0.001, Student's t test (B, D, and F-H); ANOVA (E).
